Randomized trial comparing 600- with 300-mg loading dose of clopidogrel in patients with non–ST elevation acute coronary syndrome undergoing percutaneous coronary intervention: Results of the Platelet Responsiveness to Aspirin and Clopidogrel and Troponin Increment after Coronary intervention in Acute coronary Lesions (PRACTICAL) Trial - 07/08/11
, Louise Ferguson, BAppSc a, Jim Thom, MSc a, John French, MBChB, PhD b, David Brieger, MBBS, PhD c, Derek P. Chew, MBBS, MPH d, Ron Dick, MBBS e, David Eccleston, MBBS, MMedSci f, Bernard Hockings, MD, BS g, Darren Walters, MBBS, Mphil h, Alan Whelan, MBBS, BSc i, John W. Eikelboom, MBBS jRésumé |
Background |
There is uncertainty about the benefit of a higher loading dose (LD) of clopidogrel in patients with non–ST elevation acute coronary syndrome (NSTEACS) undergoing early percutaneous coronary intervention (PCI).
Methods |
We compared the effects of a 600- versus a 300-mg LD of clopidogrel on inhibition of platelet aggregation, myonecrosis, and clinical outcomes in patients with NSTEACS undergoing an early invasive management strategy. Patients with NSTEACS (n = 256, mean age 63 years, 81.6% elevated troponin) without thienopyridine for at least 7 days were randomized to receive 600- or 300-mg LD of clopidogrel. Percutaneous coronary intervention was performed in 140 patients, with glycoprotein IIb/IIIa inhibitor use in 68.6%. Adenosine diphosphate (ADP)–induced platelet aggregation was measured by optical platelet aggregometry immediately before coronary angiography.
Results |
Post-PCI myonecrosis was defined as a next-day troponin I greater than 5 times the upper limit of reference range and greater than baseline levels. Clopidogrel 600-mg LD compared with 300-mg LD was associated with significantly reduced ADP-induced platelet aggregation (49.7% vs 55.7% with ADP 20 μmol/L) but did not reduce post-PCI myonecrosis or adverse clinical outcomes to 6 months. There was no association between preprocedural platelet aggregation and outcome.
Conclusions |
These data confirm a modest incremental antiplatelet effect of a 600-mg clopidogrel LD compared with 300-mg LD but provide no support for a clinical benefit in patients with NSTEACS managed with an early invasive strategy including a high rate (69%) of glycoprotein IIb/IIIa inhibitor use during PCI.
Le texte complet de cet article est disponible en PDF.Plan
| Clinical Trial Registration Information: Australian Clinical Trials Registry (www.actr.org.au/) number ACTRN012605000581662. |
|
| This study was supported by an unrestricted educational grant from Sanofi-Aventis, Sydney, Australia. |
Vol 157 - N° 1
P. 60.e1-60.e9 - janvier 2009 Retour au numéro
Article précédent
- Association between language and risk factor levels among Hispanic adults with hypertension, hypercholesterolemia, or diabetes
- Pracha P. Eamranond, Anna T.R. Legedza, Ana V. Diez-Roux, Namratha R. Kandula, Walter Palmas, David S. Siscovick, Kenneth J. Mukamal
- Acute coronary syndrome emergency treatment strategies: Improved treatment and reduced mortality in patients with acute coronary syndrome using guideline-based critical care pathways
- John C. Corbelli, David M. Janicke, Mark J. Cziraky, Tracey A. Hoy, Jennifer A. Corbelli
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?